Biomedical Innovation Meeting From Energy and Commerce Shows Possible Legislative Roadmap
This article was originally published in The Pink Sheet Daily
Committee solicits feedback on the 2012 PCAST report on propelling drug innovation as it looks to craft legislation to speed biomedical innovation – but nearly all topics have already been addressed by stakeholders.
You may also be interested in...
House Energy and Commerce committee says it’s committed to a bill to accelerate U.S. biomedical innovation before the next FDA user fee cycle, but the wide scope of needs and stakeholders may make crafting legislation challenging – never mind getting it passed.
A limited population antibacterial drug pathway could reassure investors about the viability of antibiotics and help FDA avoid looking over its shoulder as it approves products based on limited data, though enactment is uncertain.
Presidential advisory panel makes eight recommendations to improve innovation in drug discovery, development and evaluation; calls for broad partnership of stakeholders to accelerate therapeutics, $40 million annual appropriations for FDA’s Sentinel System.